Executive Summary
Market Introduction & Definition
Market Size & Forecast
3.1 Global Market Size (Value & Volume)
3.2 Regional Market Size & Share
Segments Analysis
4.1 By Vaccine Type (Inactivated Polio Vaccine-IPV, Oral Polio Vaccine-OPV, Novel OPV)
4.2 By Vaccine Formulation (Trivalent, Bivalent, Monovalent)
4.3 By End-User (Government Immunization Programs, Private Healthcare Providers)
4.4 By Distribution Channel (Public Procurement, Private Sector)
Competitive Landscape
5.1 Key Players & Company Profiles (with Hyperlinks)
5.2 Strategic Developments & Expansions
Market Dynamics
6.1 Drivers
6.2 Challenges & Restraints
6.3 Opportunities
Trend Analysis (IPV Transition, Combination Vaccines, Thermostable Formulations)
Strategic Frameworks
8.1 Porter’s Five Forces Analysis
8.2 SWOT Analysis (Global Market)
8.3 Value Chain Analysis
Geopolitical Impact: The USA-Israel-Iran Conflict
Regional Analysis
10.1 North America
10.2 Europe
10.3 Asia-Pacific (China, Japan, India, Southeast Asia)
10.4 Middle East & Africa
10.5 Central & South America
Quick Recommendations for Stakeholders
Conclusion
This report provides a comprehensive analysis of the global Polio (Poliomyelitis) Vaccines market, a critical segment of the global immunization landscape. Poliomyelitis is a highly infectious viral disease that primarily affects children under five years of age, and vaccination remains the cornerstone of global eradication efforts .
The global polio vaccines market was valued at approximately USD 3.67 billion in 2025 and is projected to reach USD 5.89 billion by 2032, growing at a CAGR of 6.1% during the forecast period . A more conservative estimate places the market at USD 182 million by 2031, with a CAGR of 2.3%, reflecting the shifting focus from mass campaigns to routine immunization and stockpiling as eradication nears . This growth is driven by global eradication initiatives led by WHO, Gavi, and UNICEF, along with government mandates for routine childhood immunization in over 138 countries .
The market is characterized by a mix of multinational pharmaceutical giants and emerging market manufacturers. Sanofi and GSK dominate the IPV segment, while Serum Institute of India and Bibcol are key players in the OPV market. However, the market faces significant challenges, including cold chain logistics hurdles, the emergence of vaccine-derived poliovirus (VDPV) cases, and geopolitical instability that threatens supply chains .
Poliomyelitis (Polio) is a crippling and potentially deadly infectious disease caused by the poliovirus. The virus spreads from person to person, invading the nervous system and causing paralysis in a small percentage of cases . While most infections are asymptomatic, approximately 1% of cases result in irreversible paralysis, with a mortality rate of 5-15% among paralytic cases .
Polio Vaccines are biological preparations that provide immunity against poliovirus. There are two main types :
Inactivated Polio Vaccine (IPV): Administered via intramuscular injection. It contains inactivated (killed) virus and cannot cause disease. IPV is the vaccine of choice in countries that have eliminated polio, as it carries no risk of vaccine-derived poliovirus.
Oral Polio Vaccine (OPV): Administered as oral drops. It contains live, attenuated (weakened) virus. OPV is preferred for mass campaigns in endemic regions due to its ease of administration, low cost, and ability to provide intestinal immunity that curbs virus transmission.
The global polio vaccines market is projected to grow from USD 3.67 billion in 2025 to USD 5.89 billion by 2032, reflecting a CAGR of 6.1% . This growth is primarily attributed to the transition from OPV to IPV in routine immunization schedules, which requires higher-cost injectable vaccines, and the ongoing need for outbreak response stockpiles.
In volume terms, over 500 million doses were distributed worldwide in 2024, a 12% increase from the previous year . The Global Polio Eradication Initiative (GPEI) maintains an emergency stockpile of over 100 million doses of monovalent OPV for rapid outbreak response .
Asia-Pacific: The largest and fastest-growing market, driven by large-scale immunization programs in India, Indonesia, and China. India has significantly increased its vaccine procurement budget by 18-22% annually since 2020 .
North America: A high-value, mature market focused on IPV. The CDC recommends four doses of IPV between ages 2 months and 6 years, ensuring stable demand .
Europe: A stable market with strong adoption of combination vaccines (e.g., hexavalent vaccines) that include IPV. Germany, France, and the UK are key contributors.
Inactivated Polio Vaccine (IPV): This segment is growing rapidly due to the global switch from trivalent OPV to IPV in routine immunization. IPV eliminates the risk of vaccine-derived poliovirus (VDPV) and is increasingly preferred in developed and middle-income countries .
Oral Polio Vaccine (OPV): Still the backbone of mass eradication campaigns in endemic regions. The market is shifting toward bivalent OPV (bOPV), which targets types 1 and 3 poliovirus, replacing trivalent OPV (tOPV) to reduce VDPV risk .
Novel Oral Polio Vaccine (nOPV): A recent innovation engineered to be more genetically stable than traditional OPV, with a lower risk of reverting to virulence. nOPV is being deployed in outbreak response under WHO Emergency Use Listing.
Government Immunization Programs: Dominate the market, accounting for the majority of volume through UNICEF and Gavi procurement for low-income countries. Public sector procurement is estimated to account for over 70% of global doses .
Private Healthcare Providers: A smaller but high-value segment in developed countries, where parents may opt for pediatrician-administered combination vaccines for convenience.
Public Procurement: The primary channel for low- and middle-income countries, driven by Gavi co-financing and government budgets. This channel is highly price-sensitive and characterized by long-term supply agreements.
Private Sector: Includes hospitals, clinics, and pharmacies in high-income countries. This channel is driven by consumer preference for combination vaccines and convenient administration schedules.
The market is semi-consolidated, with a clear division between multinational leaders in IPV and regional leaders in OPV.
Sanofi S.A. (France): The global leader in IPV. Sanofi's IMOVAX® POLIO is a cornerstone of routine immunization in developed countries. The company also supplies IPV as a component of combination vaccines like Pentacel® and Hexaxim®.
GlaxoSmithKline plc (GSK) (United Kingdom): A major competitor with a strong IPV portfolio. GSK's polio vaccines are often combined with DTaP and hepatitis B antigens in products like Pediarix® .
Serum Institute of India Pvt. Ltd. (India): The world's largest vaccine manufacturer by volume. Serum Institute has supplied over 1 billion doses of bOPV to the GPEI and is a critical supplier for global eradication efforts .
Bharat Biotech (Bibcol) (India): A key manufacturer of IPV, supplying to UNICEF and the Indian government under the brand name BIOPOLIO®.
Panacea Biotec Ltd (India): A significant player in OPV and combination vaccines, with a strong presence in India and international markets.
Beijing Tiantan Biological Products Co., Ltd. (China): The leading Chinese manufacturer of polio vaccines, supplying the domestic market and WHO pre-qualified markets.
IMBCAMS (IMBCA) (China): A state-backed research institute and manufacturer of vaccines in China.
Bio-Med (Pakistan): A regional manufacturer critical to polio eradication in endemic regions.
Halfkin Bio-Pharmaceuticals (China): A specialized vaccine manufacturer.
Sinovac Biotech Ltd. (China): An emerging player in the vaccine space.
Sanofi and GSK continue to focus on combination vaccines and improving IPV production yield.
Serum Institute has expanded its IPV capacity to meet global demand as countries transition away from OPV.
Bharat Biotech has invested in novel vaccine delivery technologies, including needle-free administration research.
Global Eradication Initiatives: The WHO's Global Polio Eradication Initiative (GPEI) has a $5.1 billion budget (2022-2026) for vaccine procurement and delivery, ensuring sustained demand .
Government Mandates: Routine immunization requirements in 138 countries create predictable, long-term demand cycles .
Rising Awareness: Increased public health awareness and the success of vaccination campaigns are driving sustained demand.
Cold Chain Logistics: Nearly 25% of vaccine doses in Sub-Saharan Africa and South Asia are compromised due to cold chain failures, leading to wastage and ineffective immunization . Logistics account for up to 40% of vaccine delivery costs in these markets.
Vaccine-Derived Poliovirus (VDPV): The emergence of VDPV cases—though rare (fewer than 1 per million OPV doses)—creates hesitancy and complicates eradication efforts .
Financing Gaps: Projected financing for 2025-2028 shows a 15% shortfall against requirements, threatening long-term manufacturing investments .
IPV Capacity Expansion: With over 100 million additional IPV doses needed annually to meet WHO's Immunization Agenda 2030 targets, manufacturers have significant growth opportunities .
Thermostable Formulations: Early-stage trials of microarray patches could reduce cold chain dependency by 60%, revolutionizing last-mile delivery .
Combination Vaccines: The growing demand for pentavalent and hexavalent vaccines (DTP-HepB-Hib-IPV) in developed and emerging markets offers high-value opportunities .
Transition from OPV to IPV: Over 90 countries now incorporate at least one dose of IPV into routine immunization schedules, minimizing the risk of VDPV while maintaining population immunity .
Combination Vaccine Adoption: Hexavalent vaccines are gaining traction in Europe and North America, improving vaccination compliance rates (currently averaging 86% for polio in developed nations) .
Technological Advancements: Manufacturers are adopting Vero cell culture platforms, which improve IPV yield by up to 30% compared to traditional methods . Novel adjuvants and intradermal delivery systems are also being explored.
Outbreak Response Stockpiling: The GPEI maintains a large stockpile for rapid response. In 2024, rapid response teams vaccinated 25 million children within six weeks of outbreak detection .
Threat of New Entrants (Medium): High regulatory barriers (WHO pre-qualification) and capital-intensive production facilities limit entry. However, emerging market manufacturers are entering through technology transfer and government support.
Bargaining Power of Buyers (High): UNICEF and Gavi are dominant buyers, wielding significant pricing power. They have successfully reduced vaccine prices through competitive tenders.
Bargaining Power of Suppliers (Medium): Dependence on specialized cell culture media and adjuvants creates some supplier power, but major manufacturers are vertically integrated.
Threat of Substitutes (Low): No effective substitute for polio vaccines exists. However, combination vaccines can substitute for standalone polio vaccines in some markets.
Competitive Rivalry (High): Intense competition between multinationals (Sanofi, GSK) and emerging market players (Serum Institute, Bharat Biotech) is driving price pressure, especially in the public procurement market.
Strengths: Highly effective vaccines with decades of proven safety; strong global public health infrastructure (GPEI); established cold chain logistics in many regions.
Weaknesses: Cold chain dependency; safety concerns with OPV; high cost of IPV relative to OPV; financing gaps.
Opportunities: Novel delivery technologies (patches, thermostable formulations); expansion of IPV production; increasing demand for combination vaccines; public-private partnerships.
Threats: Geopolitical instability disrupting supply chains; vaccine hesitancy; emergence of VDPV; funding volatility.
The value chain begins with raw material suppliers providing cell culture media, adjuvants, and viral strains. Manufacturers (Sanofi, GSK, Serum Institute) produce the vaccines in specialized facilities. Distributors and logistics providers manage the cold chain. Public and private healthcare providers administer vaccines. Global health organizations (WHO, UNICEF, Gavi) coordinate procurement and distribution. End-users are primarily children under five years of age .
The escalating conflict involving the USA, Israel, and Iran introduces significant volatility to the global polio vaccine market, primarily through its impact on supply chains and immunization campaigns.
Disruption of Mass Vaccination Campaigns: The Middle East remains a region where polio outbreaks have occurred, and mass vaccination campaigns are critical. Conflict zones—including parts of Iran, Syria, and Yemen—have historically been pockets of low immunization coverage. Escalation of military activity would severely disrupt these campaigns, creating unvaccinated pockets that could become reservoirs for virus transmission.
Cold Chain Logistics and Sanctions: The conflict threatens the Strait of Hormuz, a critical chokepoint for global trade. Disruption would delay the shipment of vaccines and cold chain equipment to the region. Furthermore, US sanctions on Iran could complicate procurement of vaccines and logistics services, potentially hindering eradication efforts in a country that remains vulnerable to importation of wild poliovirus.
Supply Chain Diversion: As global attention and resources shift to conflict zones, funding for polio eradication could be diverted. The GPEI relies heavily on donor funding, and geopolitical instability can lead to donor fatigue and reallocation of resources toward humanitarian aid in conflict zones.
North America: A stable, high-value IPV market driven by the CDC's routine childhood schedule and strong private sector demand for combination vaccines. The US accounts for over 85% of regional revenue .
Europe: A mature market with a strong preference for combination vaccines. Western European countries have transitioned entirely to IPV, while Eastern Europe maintains higher OPV usage.
Asia-Pacific: The largest and most dynamic market. China, India, and Indonesia are major manufacturers and consumers. India has dramatically increased its vaccine procurement budget, while Indonesia's Bio Farma is a key regional supplier .
Middle East & Africa: A region of high risk due to conflict and infrastructure challenges. The GPEI focuses significant resources on this region. Recent outbreaks of circulating vaccine-derived poliovirus (cVDPV) in nearly 30 countries have prompted emergency vaccination campaigns .
Central & South America: A region that has successfully eliminated polio. The market is focused on maintaining high routine immunization coverage and outbreak response preparedness.
For Manufacturers:
Expand IPV Capacity: With the global shift away from OPV, invest in IPV production capacity to capture growing demand.
Develop Thermostable Formulations: Prioritize R&D for thermostable vaccines and microarray patches to overcome cold chain challenges in endemic regions.
Diversify Supply Chains: Mitigate geopolitical risk by establishing regional production hubs and sourcing raw materials from multiple regions.
For Public Health Organizations (WHO, UNICEF):
Strengthen Cold Chain Infrastructure: Invest in last-mile cold chain solutions, particularly in conflict-affected regions.
Secure Long-Term Financing: Work with donor governments to secure predictable, long-term funding to avoid supply disruptions.
Address Vaccine Hesitancy: Implement community engagement programs to counter misinformation and build trust in vaccination.
For Investors:
Focus on IPV Leaders: Companies with strong IPV and combination vaccine portfolios (Sanofi, GSK) are well-positioned for long-term growth.
Monitor Emerging Market Players: Serum Institute and Bharat Biotech offer growth opportunities through their cost-effective production models and expanding international footprints.
Assess Geopolitical Risk: The Middle East and parts of Africa present both opportunity and risk. Monitor the impact of conflict on immunization campaigns and supply chains.
The global Polio (Poliomyelitis) Vaccines market is at a critical juncture. While the world is closer than ever to eradicating polio, the final stages of the eradication effort are the most complex and expensive. Sustained growth is expected, driven by the transition to IPV, the expansion of combination vaccines, and ongoing outbreak response needs. However, the market faces significant headwinds from cold chain challenges, financing gaps, and geopolitical instability, particularly the USA-Israel-Iran conflict, which threatens to disrupt campaigns in key regions. The organizations and companies that will succeed are those that innovate in vaccine delivery, build resilient supply chains, and maintain unwavering commitment to the global eradication goal.
Table of Contents
Global Polio (Poliomyelitis) Vaccines Sales Market Report
1 Polio (Poliomyelitis) Vaccines Market Overview
1.1 Product Overview and Scope of Polio (Poliomyelitis) Vaccines
1.2 Classification of Polio (Poliomyelitis) Vaccines by Product Category
1.2.1 Global Polio (Poliomyelitis) Vaccines Market Size (Sales) Comparison by Type
1.2.2 Global Polio (Poliomyelitis) Vaccines Market Size (Sales) Market Share by Type (Product Category) in
1.2.3 Inactivated Polio Vaccine (IPV)
1.2.4 Oral Polio Vaccine (OPV)
1.3 Global Polio (Poliomyelitis) Vaccines Market by Application/End Users
1.3.1 Global Polio (Poliomyelitis) Vaccines Sales (Volume) and Market Share Comparison by Application
1.3.1 Research & Academic Laboratories
1.3.2 Pharmaceutical & Biotechnology Companies
1.3.3 Others
1.4 Global Polio (Poliomyelitis) Vaccines Market by Region
1.4.1 Global Polio (Poliomyelitis) Vaccines Market Size (Value) Comparison by Region
1.4.2 United States Polio (Poliomyelitis) Vaccines Status and Prospect
1.4.3 Europe Polio (Poliomyelitis) Vaccines Status and Prospect
1.4.4 China Polio (Poliomyelitis) Vaccines Status and Prospect
1.4.5 Japan Polio (Poliomyelitis) Vaccines Status and Prospect
1.4.6 Southeast Asia Polio (Poliomyelitis) Vaccines Status and Prospect
1.4.7 India Polio (Poliomyelitis) Vaccines Status and Prospect
1.5 Global Market Size (Value and Volume) of Polio (Poliomyelitis) Vaccines
1.5.1 Global Polio (Poliomyelitis) Vaccines Sales and Growth Rate
1.5.2 Global Polio (Poliomyelitis) Vaccines Revenue and Growth Rate
2 Global Polio (Poliomyelitis) Vaccines Competition by Players/Suppliers, Type and Application
2.1 Global Polio (Poliomyelitis) Vaccines Market Competition by Players/Suppliers
2.1.1 Global Polio (Poliomyelitis) Vaccines Sales and Market Share of Key Players/Suppliers
2.1.2 Global Polio (Poliomyelitis) Vaccines Revenue and Share by Players/Suppliers
2.2 Global Polio (Poliomyelitis) Vaccines (Volume and Value) by Type
2.2.1 Global Polio (Poliomyelitis) Vaccines Sales and Market Share by Type
2.2.2 Global Polio (Poliomyelitis) Vaccines Revenue and Market Share by Type
2.3 Global Polio (Poliomyelitis) Vaccines (Volume and Value) by Region
2.3.1 Global Polio (Poliomyelitis) Vaccines Sales and Market Share by Region
2.3.2 Global Polio (Poliomyelitis) Vaccines Revenue and Market Share by Region
2.4 Global Polio (Poliomyelitis) Vaccines (Volume) by Application
3 United States Polio (Poliomyelitis) Vaccines (Volume, Value and Sales Price)
3.1 United States Polio (Poliomyelitis) Vaccines Sales and Value
3.1.1 United States Polio (Poliomyelitis) Vaccines Sales and Growth Rate
3.1.2 United States Polio (Poliomyelitis) Vaccines Revenue and Growth Rate
3.1.3 United States Polio (Poliomyelitis) Vaccines Sales Price Trend
3.2 United States Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Players
3.3 United States Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Type
3.4 United States Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Application
4 Europe Polio (Poliomyelitis) Vaccines (Volume, Value and Sales Price)
4.1 Europe Polio (Poliomyelitis) Vaccines Sales and Value
4.1.1 Europe Polio (Poliomyelitis) Vaccines Sales and Growth Rate
4.1.2 Europe Polio (Poliomyelitis) Vaccines Revenue and Growth Rate
4.1.3 Europe Polio (Poliomyelitis) Vaccines Sales Price Trend
4.2 Europe Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Players
4.3 Europe Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Type
4.4 Europe Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Application
5 China Polio (Poliomyelitis) Vaccines (Volume, Value and Sales Price)
5.1 China Polio (Poliomyelitis) Vaccines Sales and Value
5.1.1 China Polio (Poliomyelitis) Vaccines Sales and Growth Rate
5.1.2 China Polio (Poliomyelitis) Vaccines Revenue and Growth Rate
5.1.3 China Polio (Poliomyelitis) Vaccines Sales Price Trend
5.2 China Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Players
5.3 China Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Type
5.4 China Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Application
6 Japan Polio (Poliomyelitis) Vaccines (Volume, Value and Sales Price)
6.1 Japan Polio (Poliomyelitis) Vaccines Sales and Value
6.1.1 Japan Polio (Poliomyelitis) Vaccines Sales and Growth Rate
6.1.2 Japan Polio (Poliomyelitis) Vaccines Revenue and Growth Rate
6.1.3 Japan Polio (Poliomyelitis) Vaccines Sales Price Trend
6.2 Japan Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Players
6.3 Japan Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Type
6.4 Japan Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Application
7 Southeast Asia Polio (Poliomyelitis) Vaccines (Volume, Value and Sales Price)
7.1 Southeast Asia Polio (Poliomyelitis) Vaccines Sales and Value
7.1.1 Southeast Asia Polio (Poliomyelitis) Vaccines Sales and Growth Rate
7.1.2 Southeast Asia Polio (Poliomyelitis) Vaccines Revenue and Growth Rate
7.1.3 Southeast Asia Polio (Poliomyelitis) Vaccines Sales Price Trend
7.2 Southeast Asia Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Players
7.3 Southeast Asia Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Type
7.4 Southeast Asia Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Application
8 India Polio (Poliomyelitis) Vaccines (Volume, Value and Sales Price)
8.1 India Polio (Poliomyelitis) Vaccines Sales and Value
8.1.1 India Polio (Poliomyelitis) Vaccines Sales and Growth Rate
8.1.2 India Polio (Poliomyelitis) Vaccines Revenue and Growth Rate
8.1.3 India Polio (Poliomyelitis) Vaccines Sales Price Trend
8.2 India Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Players
8.3 India Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Type
8.4 India Polio (Poliomyelitis) Vaccines Sales Volume and Market Share by Application
9 Global Polio (Poliomyelitis) Vaccines Players/Suppliers Profiles and Sales Data
9.1 Sanofi
9.1.1 Company Basic Information, Manufacturing Base and Competitors
9.1.2 Polio (Poliomyelitis) Vaccines Product Category, Application and Specification
9.1.2.1 Product A
9.1.2.2 Product B
9.1.3 Sanofi Polio (Poliomyelitis) Vaccines Sales, Revenue, Price and Gross Margin
9.1.4 Main Business/Business Overview
9.2 GSK
9.2.1 Company Basic Information, Manufacturing Base and Competitors
9.2.2 Polio (Poliomyelitis) Vaccines Product Category, Application and Specification
9.2.2.1 Product A
9.2.2.2 Product B
9.2.3 GSK Polio (Poliomyelitis) Vaccines Sales, Revenue, Price and Gross Margin
9.2.4 Main Business/Business Overview
9.3 Bibcol
9.3.1 Company Basic Information, Manufacturing Base and Competitors
9.3.2 Polio (Poliomyelitis) Vaccines Product Category, Application and Specification
9.3.2.1 Product A
9.3.2.2 Product B
9.3.3 Bibcol Polio (Poliomyelitis) Vaccines Sales, Revenue, Price and Gross Margin
9.3.4 Main Business/Business Overview
9.4 Serum Institute
9.4.1 Company Basic Information, Manufacturing Base and Competitors
9.4.2 Polio (Poliomyelitis) Vaccines Product Category, Application and Specification
9.4.2.1 Product A
9.4.2.2 Product B
9.4.3 Serum Institute Polio (Poliomyelitis) Vaccines Sales, Revenue, Price and Gross Margin
9.4.4 Main Business/Business Overview
9.5 Tiantan Biological
9.5.1 Company Basic Information, Manufacturing Base and Competitors
9.5.2 Polio (Poliomyelitis) Vaccines Product Category, Application and Specification
9.5.2.1 Product A
9.5.2.2 Product B
9.5.3 Tiantan Biological Polio (Poliomyelitis) Vaccines Sales, Revenue, Price and Gross Margin
9.5.4 Main Business/Business Overview
9.6 IMBCA
9.6.1 Company Basic Information, Manufacturing Base and Competitors
9.6.2 Polio (Poliomyelitis) Vaccines Product Category, Application and Specification
9.6.2.1 Product A
9.6.2.2 Product B
9.6.3 IMBCA Polio (Poliomyelitis) Vaccines Sales, Revenue, Price and Gross Margin
9.6.4 Main Business/Business Overview
9.7 Panacea Biotec Ltd
9.7.1 Company Basic Information, Manufacturing Base and Competitors
9.7.2 Polio (Poliomyelitis) Vaccines Product Category, Application and Specification
9.7.2.1 Product A
9.7.2.2 Product B
9.7.3 Panacea Biotec Ltd Polio (Poliomyelitis) Vaccines Sales, Revenue, Price and Gross Margin
9.7.4 Main Business/Business Overview
9.8 Bio-Med
9.8.1 Company Basic Information, Manufacturing Base and Competitors
9.8.2 Polio (Poliomyelitis) Vaccines Product Category, Application and Specification
9.8.2.1 Product A
9.8.2.2 Product B
9.8.3 Bio-Med Polio (Poliomyelitis) Vaccines Sales, Revenue, Price and Gross Margin
9.8.4 Main Business/Business Overview
9.9 Halfkin Bio-Pharmaceuticals
9.9.1 Company Basic Information, Manufacturing Base and Competitors
9.9.2 Polio (Poliomyelitis) Vaccines Product Category, Application and Specification
9.9.2.1 Product A
9.9.2.2 Product B
9.9.3 Halfkin Bio-Pharmaceuticals Polio (Poliomyelitis) Vaccines Sales, Revenue, Price and Gross Margin
9.9.4 Main Business/Business Overview
10 Polio (Poliomyelitis) Vaccines Maufacturing Cost Analysis
10.1 Polio (Poliomyelitis) Vaccines Key Raw Materials Analysis
10.1.1 Key Raw Materials
10.1.2 Price Trend of Key Raw Materials
10.1.3 Key Suppliers of Raw Materials
10.1.4 Market Concentration Rate of Raw Materials
10.2 Proportion of Manufacturing Cost Structure
10.2.1 Raw Materials
10.2.2 Labor Cost
10.2.3 Manufacturing Process Analysis of Polio (Poliomyelitis) Vaccines
10.3 Manufacturing Process Analysis of Polio (Poliomyelitis) Vaccines
11 Industrial Chain, Sourcing Strategy and Downstream Buyers
11.1 Polio (Poliomyelitis) Vaccines Industrial Chain Analysis
11.2 Upstream Raw Materials Sourcing
11.3 Raw Materials Sources of Polio (Poliomyelitis) Vaccines Major Manufacturers in
11.4 Downstream Buyers
12 Marketing Strategy Analysis, Distributors/Traders
12.1 Marketing Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.1.3 Marketing Channel Development Trend
12.2 Market Positioning
12.2.1 Pricing Strategy
12.2.2 Brand Strategy
12.2.3 Target Client
12.3 Distributors/Traders List
13 Market Effect Factors Analysis
13.1 Technology Progress/Risk
13.1.1 Substitutes Threat
13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs/Customer Preference Change
13.3 Economic/Political Environmental Change
14 Global Polio (Poliomyelitis) Vaccines Market Forecast
14.1 Global Polio (Poliomyelitis) Vaccines Sales Volume, Revenue and Price Forecast
14.1.1 Global Polio (Poliomyelitis) Vaccines Sales Volume and Growth Rate Forecast
14.1.2 Global Polio (Poliomyelitis) Vaccines Revenue and Growth Rate Forecast
14.1.3 Global Polio (Poliomyelitis) Vaccines Price and Trend Forecast
14.2 Global Polio (Poliomyelitis) Vaccines Sales Volume, Revenue and Growth Rate Forecast by Region
14.2.1 Global Polio (Poliomyelitis) Vaccines Sales Volume and Growth Rate Forecast by Regions
14.2.2 Global Polio (Poliomyelitis) Vaccines Revenue and Growth Rate Forecast by Regions
14.2.3 United States Polio (Poliomyelitis) Vaccines Sales Volume, Revenue and Growth Rate Forecast
14.2.4 Europe Polio (Poliomyelitis) Vaccines Sales Volume, Revenue and Growth Rate Forecast
14.2.5 China Polio (Poliomyelitis) Vaccines Sales Volume, Revenue and Growth Rate Forecast
14.2.6 Japan Polio (Poliomyelitis) Vaccines Sales Volume, Revenue and Growth Rate Forecast
14.2.7 Southeast Asia Polio (Poliomyelitis) Vaccines Sales Volume, Revenue and Growth Rate Forecast
14.2.8 India Polio (Poliomyelitis) Vaccines Sales Volume, Revenue and Growth Rate Forecast
14.3 Global Polio (Poliomyelitis) Vaccines Sales Volume, Revenue and Price Forecast by Type
14.3.1 Global Polio (Poliomyelitis) Vaccines Sales Forecast by Type
14.3.2 Global Polio (Poliomyelitis) Vaccines Revenue Forecast by Type
14.3.3 Global Polio (Poliomyelitis) Vaccines Price Forecast by Type
14.4 Global Polio (Poliomyelitis) Vaccines Sales Volume Forecast by Application
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Disclaimer
List of Tables and Figures
Figure Product Picture of Polio (Poliomyelitis) Vaccines
Figure Global Polio (Poliomyelitis) Vaccines Sales Volume Comparison (K Units) by Type
Figure Global Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Type (Product Category) in
Figure Inactivated Polio Vaccine (IPV) Product Picture
Figure Oral Polio Vaccine (OPV) Product Picture
Figure Global Polio (Poliomyelitis) Vaccines Sales Comparison (K Units) by Application
Figure Global Sales Market Share of Polio (Poliomyelitis) Vaccines by Application in
Figure Research & Academic Laboratories Examples
Table Key Downstream Customer in Research & Academic Laboratories
Figure Pharmaceutical & Biotechnology Companies Examples
Table Key Downstream Customer in Pharmaceutical & Biotechnology Companies
Figure Others Examples
Table Key Downstream Customer in Others
Figure Global Polio (Poliomyelitis) Vaccines Market Size (Million USD) by Regions
Figure United States Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Growth Rate
Figure Europe Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Growth Rate
Figure China Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Growth Rate
Figure Japan Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Growth Rate
Figure Southeast Asia Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Growth Rate
Figure India Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Growth Rate
Figure Global Polio (Poliomyelitis) Vaccines Sales Volume (K Units) and Growth Rate
Figure Global Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Growth Rate
Figure Global Market Major Players Polio (Poliomyelitis) Vaccines Sales Volume (K Units)
Table Global Polio (Poliomyelitis) Vaccines Sales (K Units) of Key Players/Suppliers
Table Global Polio (Poliomyelitis) Vaccines Sales Share by Players/Suppliers
Figure Polio (Poliomyelitis) Vaccines Sales Share by Players/Suppliers
Figure Polio (Poliomyelitis) Vaccines Sales Share by Players/Suppliers
Figure Global Polio (Poliomyelitis) Vaccines Revenue (Million USD) by Players/Suppliers
Table Global Polio (Poliomyelitis) Vaccines Revenue (Million USD) by Players/Suppliers
Table Global Polio (Poliomyelitis) Vaccines Revenue Share by Players/Suppliers
Table Global Polio (Poliomyelitis) Vaccines Revenue Share by Players
Table Global Polio (Poliomyelitis) Vaccines Revenue Share by Players
Table Global Polio (Poliomyelitis) Vaccines Sales (K Units) and Market Share by Type
Table Global Polio (Poliomyelitis) Vaccines Sales Share (K Units) by Type
Figure Sales Market Share of Polio (Poliomyelitis) Vaccines by Type
Figure Global Polio (Poliomyelitis) Vaccines Sales Growth Rate by Type
Table Global Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Market Share by Type
Table Global Polio (Poliomyelitis) Vaccines Revenue Share by Type
Figure Revenue Market Share of Polio (Poliomyelitis) Vaccines by Type
Figure Global Polio (Poliomyelitis) Vaccines Revenue Growth Rate by Type
Table Global Polio (Poliomyelitis) Vaccines Sales Volume (K Units) and Market Share by Region
Table Global Polio (Poliomyelitis) Vaccines Sales Share by Region
Figure Sales Market Share of Polio (Poliomyelitis) Vaccines by Region
Figure Global Polio (Poliomyelitis) Vaccines Sales Growth Rate by Region in
Table Global Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Market Share by Region
Table Global Polio (Poliomyelitis) Vaccines Revenue Share (%) by Region
Figure Revenue Market Share of Polio (Poliomyelitis) Vaccines by Region
Figure Global Polio (Poliomyelitis) Vaccines Revenue Growth Rate by Region in
Table Global Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Market Share by Region
Table Global Polio (Poliomyelitis) Vaccines Revenue Share (%) by Region
Figure Revenue Market Share of Polio (Poliomyelitis) Vaccines by Region
Figure Global Polio (Poliomyelitis) Vaccines Revenue Market Share by Region in
Table Global Polio (Poliomyelitis) Vaccines Sales Volume (K Units) and Market Share by Application
Table Global Polio (Poliomyelitis) Vaccines Sales Share (%) by Application
Figure Sales Market Share of Polio (Poliomyelitis) Vaccines by Application
Figure Global Polio (Poliomyelitis) Vaccines Sales Market Share by Application
Figure United States Polio (Poliomyelitis) Vaccines Sales (K Units) and Growth Rate
Figure United States Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Growth Rate
Figure United States Polio (Poliomyelitis) Vaccines Sales Price (USD/Unit) Trend
Table United States Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Players
Table United States Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Players
Figure United States Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Players in
Table United States Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Type
Table United States Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Type
Figure United States Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Type in
Table United States Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Application
Table United States Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Application
Figure United States Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Application in
Figure Europe Polio (Poliomyelitis) Vaccines Sales (K Units) and Growth Rate
Figure Europe Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Growth Rate
Figure Europe Polio (Poliomyelitis) Vaccines Sales Price (USD/Unit) Trend
Table Europe Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Players
Table Europe Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Players
Figure Europe Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Players in
Table Europe Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Type
Table Europe Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Type
Figure Europe Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Type in
Table Europe Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Application
Table Europe Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Application
Figure Europe Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Application in
Figure China Polio (Poliomyelitis) Vaccines Sales (K Units) and Growth Rate
Figure China Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Growth Rate
Figure China Polio (Poliomyelitis) Vaccines Sales Price (USD/Unit) Trend
Table China Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Players
Table China Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Players
Figure China Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Players in
Table China Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Type
Table China Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Type
Figure China Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Type in
Table China Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Application
Table China Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Application
Figure China Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Application in
Figure Japan Polio (Poliomyelitis) Vaccines Sales (K Units) and Growth Rate
Figure Japan Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Growth Rate
Figure Japan Polio (Poliomyelitis) Vaccines Sales Price (USD/Unit) Trend
Table Japan Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Players
Table Japan Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Players
Figure Japan Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Players in
Table Japan Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Type
Table Japan Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Type
Figure Japan Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Type in
Table Japan Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Application
Table Japan Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Application
Figure Japan Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Application in
Figure Southeast Asia Polio (Poliomyelitis) Vaccines Sales (K Units) and Growth Rate
Figure Southeast Asia Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Growth Rate
Figure Southeast Asia Polio (Poliomyelitis) Vaccines Sales Price (USD/Unit) Trend
Table Southeast Asia Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Players
Table Southeast Asia Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Players
Figure Southeast Asia Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Players in
Table Southeast Asia Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Type
Table Southeast Asia Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Type
Figure Southeast Asia Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Type in
Table Southeast Asia Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Application
Table Southeast Asia Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Application
Figure Southeast Asia Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Application in
Figure India Polio (Poliomyelitis) Vaccines Sales (K Units) and Growth Rate
Figure India Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Growth Rate
Figure India Polio (Poliomyelitis) Vaccines Sales Price (USD/Unit) Trend
Table India Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Players
Table India Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Players
Figure India Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Players in
Table India Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Type
Table India Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Type
Figure India Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Type in
Table India Polio (Poliomyelitis) Vaccines Sales Volume (K Units) by Application
Table India Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Application
Figure India Polio (Poliomyelitis) Vaccines Sales Volume Market Share by Application in
Table Sanofi Basic Information List
Table Sanofi Polio (Poliomyelitis) Vaccines Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin
Figure Sanofi Polio (Poliomyelitis) Vaccines Sales Growth Rate
Figure Sanofi Polio (Poliomyelitis) Vaccines Sales Global Market Share
Figure Sanofi Polio (Poliomyelitis) Vaccines Revenue Global Market Share
Table GSK Basic Information List
Table GSK Polio (Poliomyelitis) Vaccines Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin
Figure GSK Polio (Poliomyelitis) Vaccines Sales Growth Rate
Figure GSK Polio (Poliomyelitis) Vaccines Sales Global Market Share
Figure GSK Polio (Poliomyelitis) Vaccines Revenue Global Market Share
Table Bibcol Basic Information List
Table Bibcol Polio (Poliomyelitis) Vaccines Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin
Figure Bibcol Polio (Poliomyelitis) Vaccines Sales Growth Rate
Figure Bibcol Polio (Poliomyelitis) Vaccines Sales Global Market Share (-
Figure Bibcol Polio (Poliomyelitis) Vaccines Revenue Global Market Share
Table Serum Institute Basic Information List
Table Serum Institute Polio (Poliomyelitis) Vaccines Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin
Figure Serum Institute Polio (Poliomyelitis) Vaccines Sales Growth Rate
Figure Serum Institute Polio (Poliomyelitis) Vaccines Sales Global Market Share
Figure Serum Institute Polio (Poliomyelitis) Vaccines Revenue Global Market Share
Table Tiantan Biological Basic Information List
Table Tiantan Biological Polio (Poliomyelitis) Vaccines Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin
Figure Tiantan Biological Polio (Poliomyelitis) Vaccines Sales Growth Rate
Figure Tiantan Biological Polio (Poliomyelitis) Vaccines Sales Global Market Share
Figure Tiantan Biological Polio (Poliomyelitis) Vaccines Revenue Global Market Share
Table IMBCA Basic Information List
Table IMBCA Polio (Poliomyelitis) Vaccines Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin
Figure IMBCA Polio (Poliomyelitis) Vaccines Sales Growth Rate
Figure IMBCA Polio (Poliomyelitis) Vaccines Sales Global Market Share (-
Figure IMBCA Polio (Poliomyelitis) Vaccines Revenue Global Market Share
Table Panacea Biotec Ltd Basic Information List
Table Panacea Biotec Ltd Polio (Poliomyelitis) Vaccines Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin
Figure Panacea Biotec Ltd Polio (Poliomyelitis) Vaccines Sales Growth Rate
Figure Panacea Biotec Ltd Polio (Poliomyelitis) Vaccines Sales Global Market Share
Figure Panacea Biotec Ltd Polio (Poliomyelitis) Vaccines Revenue Global Market Share
Table Bio-Med Basic Information List
Table Bio-Med Polio (Poliomyelitis) Vaccines Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin
Figure Bio-Med Polio (Poliomyelitis) Vaccines Sales Growth Rate
Figure Bio-Med Polio (Poliomyelitis) Vaccines Sales Global Market Share (-
Figure Bio-Med Polio (Poliomyelitis) Vaccines Revenue Global Market Share
Table Halfkin Bio-Pharmaceuticals Basic Information List
Table Halfkin Bio-Pharmaceuticals Polio (Poliomyelitis) Vaccines Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin
Figure Halfkin Bio-Pharmaceuticals Polio (Poliomyelitis) Vaccines Sales Growth Rate
Figure Halfkin Bio-Pharmaceuticals Polio (Poliomyelitis) Vaccines Sales Global Market Share
Figure Halfkin Bio-Pharmaceuticals Polio (Poliomyelitis) Vaccines Revenue Global Market Share
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Polio (Poliomyelitis) Vaccines
Figure Manufacturing Process Analysis of Polio (Poliomyelitis) Vaccines
Figure Polio (Poliomyelitis) Vaccines Industrial Chain Analysis
Table Raw Materials Sources of Polio (Poliomyelitis) Vaccines Major Players in
Table Major Buyers of Polio (Poliomyelitis) Vaccines
Table Distributors/Traders List
Figure Global Polio (Poliomyelitis) Vaccines Sales Volume (K Units) and Growth Rate Forecast
Figure Global Polio (Poliomyelitis) Vaccines Revenue (Million USD) and Growth Rate Forecast
Figure Global Polio (Poliomyelitis) Vaccines Price (USD/Unit) and Trend Forecast
Table Global Polio (Poliomyelitis) Vaccines Sales Volume (K Units) Forecast by Regions
Figure Global Polio (Poliomyelitis) Vaccines Sales Volume Market Share Forecast by Regions
Figure Global Polio (Poliomyelitis) Vaccines Sales Volume Market Share Forecast by Regions in
Table Global Polio (Poliomyelitis) Vaccines Revenue (Million USD) Forecast by Regions
Figure Global Polio (Poliomyelitis) Vaccines Revenue Market Share Forecast by Regions
Figure Global Polio (Poliomyelitis) Vaccines Revenue Market Share Forecast by Regions in
Figure United States Polio (Poliomyelitis) Vaccines Sales Volume (K Units) and Growth Rate Forecast
Figure United States Polio (Po
Sanofi S.A. (France): The global leader in IPV. Sanofi's IMOVAX® POLIO is a cornerstone of routine immunization in developed countries. The company also supplies IPV as a component of combination vaccines like Pentacel® and Hexaxim®.
GlaxoSmithKline plc (GSK) (United Kingdom): A major competitor with a strong IPV portfolio. GSK's polio vaccines are often combined with DTaP and hepatitis B antigens in products like Pediarix® .
Serum Institute of India Pvt. Ltd. (India): The world's largest vaccine manufacturer by volume. Serum Institute has supplied over 1 billion doses of bOPV to the GPEI and is a critical supplier for global eradication efforts .
Bharat Biotech (Bibcol) (India): A key manufacturer of IPV, supplying to UNICEF and the Indian government under the brand name BIOPOLIO®.
Panacea Biotec Ltd (India): A significant player in OPV and combination vaccines, with a strong presence in India and international markets.
Beijing Tiantan Biological Products Co., Ltd. (China): The leading Chinese manufacturer of polio vaccines, supplying the domestic market and WHO pre-qualified markets.
IMBCAMS (IMBCA) (China): A state-backed research institute and manufacturer of vaccines in China.
Bio-Med (Pakistan): A regional manufacturer critical to polio eradication in endemic regions.
Halfkin Bio-Pharmaceuticals (China): A specialized vaccine manufacturer.
Sinovac Biotech Ltd. (China): An emerging player in the vaccine space.
Upto 24 to 48 hrs (Working Hours)
Upto 72 hrs max (Working Hours) - Weekends and Public Holidays
Single User License - Allows access to only one person to the report.
Multi User License - Allows sharing with max 5 persons within organization.
Corporate License – Can be shared across entire organization.
Online Payments with PayPal
Wire Transfer / Bank Transfer
At ChemReports, we understand that business decisions can’t wait. Our research specialists are available anytime to answer your queries and guide you through our reports, ensuring quick and reliable assistance.
ChemReports provides 360° market analysis across materials, technologies, and global chemical sectors—helping you make confident business decisions.
We turn complex data into strategic insights to support fact-based decisions, market entry strategies, and competitive analysis.
Your personal and business information is completely secure with us. We value your trust and ensure strict confidentiality.
Need tailored insights? Our analysts provide custom reports built on authentic data and aligned with your specific business goals.